PTCT
Price
$46.74
Change
-$1.63 (-3.37%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
3.69B
21 days until earnings call
XNCR
Price
$8.90
Change
-$0.92 (-9.37%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
627.11M
35 days until earnings call
Ad is loading...

PTCT vs XNCR

Header iconPTCT vs XNCR Comparison
Open Charts PTCT vs XNCRBanner chart's image
PTC Therapeutics
Price$46.74
Change-$1.63 (-3.37%)
Volume$16.55K
Capitalization3.69B
Xencor
Price$8.90
Change-$0.92 (-9.37%)
Volume$31.01K
Capitalization627.11M
PTCT vs XNCR Comparison Chart
Loading...
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTCT vs. XNCR commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTCT is a Hold and XNCR is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (PTCT: $48.37 vs. XNCR: $9.82)
Brand notoriety: PTCT and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTCT: 111% vs. XNCR: 116%
Market capitalization -- PTCT: $3.69B vs. XNCR: $627.11M
PTCT [@Biotechnology] is valued at $3.69B. XNCR’s [@Biotechnology] market capitalization is $627.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTCT’s FA Score shows that 0 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • PTCT’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, both PTCT and XNCR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTCT’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).

  • PTCT’s TA Score: 5 bullish, 4 bearish.
  • XNCR’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both PTCT and XNCR are a good buy in the short-term.

Price Growth

PTCT (@Biotechnology) experienced а -12.55% price change this week, while XNCR (@Biotechnology) price change was -11.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

PTCT is expected to report earnings on Apr 24, 2025.

XNCR is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTCT($3.69B) has a higher market cap than XNCR($627M). PTCT YTD gains are higher at: 7.156 vs. XNCR (-57.267). PTCT has higher annual earnings (EBITDA): -120.46M vs. XNCR (-186.17M). PTCT has more cash in the bank: 1.14B vs. XNCR (498M). XNCR has less debt than PTCT: XNCR (232M) vs PTCT (2.47B). PTCT has higher revenues than XNCR: PTCT (807M) vs XNCR (110M).
PTCTXNCRPTCT / XNCR
Capitalization3.69B627M588%
EBITDA-120.46M-186.17M65%
Gain YTD7.156-57.267-12%
P/E RatioN/AN/A-
Revenue807M110M734%
Total Cash1.14B498M229%
Total Debt2.47B232M1,065%
FUNDAMENTALS RATINGS
PTCT vs XNCR: Fundamental Ratings
PTCT
XNCR
OUTLOOK RATING
1..100
5651
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4595
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XNCR's Valuation (79) in the Biotechnology industry is in the same range as PTCT (99). This means that XNCR’s stock grew similarly to PTCT’s over the last 12 months.

XNCR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PTCT (100). This means that XNCR’s stock grew similarly to PTCT’s over the last 12 months.

XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as PTCT (100). This means that XNCR’s stock grew similarly to PTCT’s over the last 12 months.

PTCT's Price Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for XNCR (95). This means that PTCT’s stock grew somewhat faster than XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for PTCT (100). This means that XNCR’s stock grew significantly faster than PTCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTCTXNCR
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 18 days ago
76%
Bullish Trend 15 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
62%
Aroon
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
PTCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTADX49.14N/A
N/A
Fidelity Advisor International Discv M
CCPIX45.28N/A
N/A
Calvert Mid-Cap I
PLLAX23.46N/A
N/A
Principal SmallCap A
CGEZX18.71N/A
N/A
Columbia Select Global Equity Inst
HWGIX14.77N/A
N/A
Hotchkis & Wiley Global Value I